A Review on Anti-CD19 CAR T Therapy against B-Cell Malignancies and Future Implications
DOI:
https://doi.org/10.15173/sciential.v1i4.2435Keywords:
CAR T therapy, immuno-oncology, LeukemiaAbstract
This review examines CAR T CD19 immunotherapy, a newly FDA approved targeted therapy for B-Cell Acute Lymphoblastic Leukemia treatment. This therapy utilizes modified T cells from the patient's immune system, engineered to possess an anti-CD19 receptor that can recognize the specific CD19 antigen expressed on the surface of malignant B-lymphocytes. Using this highly individualized treatment, cancer types with a high rate of metastasis or relapse can be treated by the targeted nature of this therapy. The review aims to summarize the process through which CAR T was developed, from its inception to FDA approval. The material examined is current until March 2019 and explores the mechanisms and management of CAR T cell toxicity experienced by patients undergoing treatment. Clinical trials from respective stages of development are also detailed and summarized. The viable treatment options for patients suffering from B-cell acute lymphoblastic leukemia (B-ALL) are outlined. Despite the promising remission rates of CAR T therapy, its accessibility is limited due to current cost of treatment. With advancements in technology and improved understanding of immune-based therapies, it is possible that this method can become a more viable and affordable treatment option for patients in the future.
Downloads
Published
How to Cite
Issue
Section
License
Authors submitting to the journal must adhere to the terms of Attribution-ShareAlike 4.0 International (CC BY-SA 4.0) license as outlined below:
1. You are free to share (copy and redistribute) any material from this journal, granted you have given appropriate credit, provided the link to the license, and indicated whether changes were applied to original work.
2. You are free to adapt (remix, transform, and build upon) any material from this journal, granted you distribute your work under the same license.